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Abstract
Vaginal microbicides hold great promise for the prevention of viral diseases like HIV, but the failure of several microbicide
candidates in clinical trials has raised important questions regarding the parameters to be evaluated to determine in vivo
efficacy in humans. Clinical trials of the candidate microbicides nonoxynol-9 (N9) and cellulose sulfate revealed an increase
in HIV infection, vaginal inflammation, and recruitment of HIV susceptible lymphocytes, highlighting the need to identify
biomarkers that can accurately predict microbicide toxicity early in preclinical development and in human trials. We used
quantitative proteomics and RT-PCR approaches in mice and rabbits to identify protein changes in vaginal fluid and tissue in
response to treatment with N9 or benzalkonium chloride (BZK). We compared changes generated with N9 and BZK
treatment to the changes generated in response to tenofovir gel, a candidate microbicide that holds promise as a safe and
effective microbicide. Both compounds down regulated mucin 5 subtype B, and peptidoglycan recognition protein 1 in
vaginal tissue; however, mucosal brush samples also showed upregulation of plasma proteins fibrinogen, plasminogen,
apolipoprotein A-1, and apolipoprotein C-1, which may be a response to the erosive nature of N9 and BZK. Additional
proteins down-regulated in vaginal tissue by N9 or BZK treatment include CD166 antigen, olfactomedin-4, and anterior
gradient protein 2 homolog. We also observed increases in the expression of C-C chemokines CCL3, CCL5, and CCL7 in
response to treatment. There was concordance in expression level changes for several of these proteins using both the
mouse and rabbit models. Using a human vaginal epithelial cell line, the expression of mucin 5 subtype B and olfactomedin-
4 were down-regulated in response to N9, suggesting these markers could apply to humans. These data identifies new
proteins that after further validation could become part of a panel of biomarkers to effectively evaluate microbicide toxicity.
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Introduction
Topical microbicides have been proposed as agents to prevent
the transmission of HIV by creating chemical, biological, and/or
physical barriers to infection, or by blocking or inactivating the
virus at the mucosal surface where infection can occur. An ideal
microbicide would need to demonstrate both protection against
HIV infection and low toxicity after repeated use. Although
several candidate microbicides initially appeared promising in
preclinical safety studies, they later proved to be ineffective in
clinical trials [1–13]. In some cases, they actually increased the risk
of infection, e.g. cellulose sulfate [12]. Similarly, nonoxynol-9 (N9),
a contraceptive spermicide that has previously been shown to be
safe in preclinical and phase I studies, generated disappointing
clinical data as a protective microbicide [11,13]. In fact, repetitive
use of N9 resulted in genital irritation/inflammation and increased
risk of acquiring HIV [11]. The limited success of putative
microbicides in clinical trials demonstrates a need for better
parameters to predict the safety of candidates undergoing
preclinical development. One approach is to develop a robust
series of biomarkers capable of predicting cellular and molecular
changes occurring in the vaginal mucosa/epithelium during
microbicide treatment. Such markers could have utility both in
preclinical development and, eventually, in clinical development as
well.
The current preferred pre-clinical model for assessment of
microbicide safety is the rabbit vaginal irritation (RVI) model [14–
20]. The assay requires euthanizing all study animals, endpoints of
the RVI are mostly histological, and in the recent years, the
limitations of this model in detecting potential toxicity, have
clearly demonstrated that additional parameters must be included
in the evaluation of new candidate microbicides. Recent studies
using this model have identified changes in inflammatory cytokines
in vaginal lavage fluids in response to compounds with toxic
characteristics [18,19]. Although the significance of these cytokines
has not been fully clarified, they may play a role in creating an
environment more susceptible to pathogen infection. For example,
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the presence of elevated levels of pro-inflammatory factors may
increase the proliferation of immune cells in the vaginal tissue
parenchyma or increase migration of HIV susceptible immune
cells to the vaginal tract.
Although the RVI model has been used for many years to
evaluate potential toxic effects of microbicide candidates, it is not
without shortcomings. The human and rabbit vaginal tissues show
significant structural differences (stratified squamous versus
columnar epithelium, respectively) [21,22] that may be responsible
for different susceptibilities to treatment. Moreover, the rabbit
lacks cyclic reproductive stages and cervical mucus production, all
factors that may affect the environment in the vagina [23].
More recently, mouse vaginal irritation (MVI) models have
been developed and used to evaluate microbicide safety [14,15,24–
28]. Advantages of the MVI include a well characterized immune
system and a comprehensive protein database that makes it
amenable to proteomics studies. In addition, it is significantly less
expensive than the RVI model; uses a smaller animal that requires
less test articles for safety testing; is not a USDA-regulated species;
and provides toxicological results for cross-species comparison,
making it an attractive, alternative model for pre-clinical
evaluation of vaginal microbicides.
Here, we have used both the RVI and MVI models to identify
biomarkers that could be incorporated in the safety evaluations of
vaginal anti-HIV microbicides. For our studies we selected to use
two known vaginal irritants [18,29], the spermicide N9 and the
antiseptic benzalkonium chloride (BZK) as models of toxic
compounds for vaginal administration, and we identified vaginal




Nonoxynol-9 (N9) was purchased from Spectrum Chemicals
and Laboratory Products (Gardena, CA); tenofovir was purchased
from AK Scientific (Union City, CA); benzalkonium chloride
(BZK) and high viscosity sodium carboxymethylcellulose (CMC)
were purchased from Sigma Aldrich (Saint Louis, MO); mouse
and rabbit apolipoprotein A-I, apolipoprotein C-1, CD166, and
rabbit IL-8 ELISA kits were purchased from EIAab (Wuhan,
China); mouse fibrinogen ELISA kit was purchased from Abcam
(Cambridge, MA); mouse plasminogen ELISA kit was purchased
from GenWay (San Diego, CA); mouse IL-8 ELISA kit was
purchased from MyBioSource (San Diego, CA); rabbit plasmin-
ogen ELISA kit was purchased from Alpco (Salem, NH); rabbit
fibrinogen ELISA kit was purchased from Molecular Innovations
(Novi, MI); medroxyprogesteron acetate was purchased from
Pharmacia (New York, NY); CellTiter-Glo was purchased from
Promega (Madison, WI); RNeasy kits were purchased from
Qiagen (Valencia, CA); rabbit anti-human olfactomedin 4
(OLFM-4) polyclonal antibody was purchased from Abcam
(Cambridge, MA); rabbit anti-human mucin 5B polyclonal
antibody was purchased from Bioss USA Antibodies (Woburn,
MA); rabbit anti-mouse CD166 was purchased from GeneTex
(Irvine, CA); rabbit anti-mouse b-actin was purchased from
Abcam (Cambridge, MA); IRDye 800 Goat anti-rabbit IgG was
purchased from Li-Cor (Lincoln, NE); mouse anti-human b-actin
monoclonal antibody was purchased from Cell Signaling Tech-
nology (Danvers, MA); donkey anti-mouse IgG antibody conju-
gated to IRDye 680 LT and goat anti-rabbit IgG antibody
conjugated to IRDye 800CW were purchased from LI-COR
biosciences (Lincoln, NE). Precast 4–12% Bis-Tris SDS-PAGE, 3–
8% Tris-acetate SDS-PAGE gels, and PDVF transfer membranes
were purchased from Life Technologies (Grand Island, NY);
oligonucleotides were purchased from Integrated DNA Technol-
ogies (Coralville, IA).
Microbicide preparation
8% N9, and 1% tenofovir were prepared in 2% sodium
carboxymethylcellulose, and 2% BZK was prepared in ultrapure
water. Vehicle, N9, and BZK microbicides were prepared no
more than three days prior to use and were stored at 4uC. Prior to
dosing, microbicides were allowed to reach ambient temperature.
Buffergel, was obtained from ReProtect Inc. in its clinical
formulation, and was stored at room temperature until use.
Cell lines and challenge with N9
Vk2 (E6/E7) cells (CRL-2616) were obtained from American
Type Culture Collection (Rockville, MD). Cells were grown in
keratinocyte-serum free medium (K-SFM) containing 5 ng/ml
recombinant epidermal growth factor and 50 mg/ml bovine
pituitary extract all purchased from Invitrogen Corporation
(Grand Island, NY). A maximum tolerated dose of N9 was
determined by serially diluting the microbicide from 1% to
0.001% in cell culture medium and each dilution added to
individual wells of an 80–90% confluent monolayer of Vk2 Cells
in 96-well plates. Cell viability was performed using CellTiter-Glo.
Quantitative RT-PCR
Frozen vaginas were minced and placed in RNAlater (Life
Technologies, Grand Island, NY) and stored at 220uC until
processed. Total RNA was isolated (RNeasy kit) from vaginal
tissues of 3 animals per treatment group using Ambion mirVana
Kit (Life Technologies, Grand Island, NY). cDNA was prepared
using Superscript RTII (Life Technologies, Grand Island, NY).
Quantitative RT-PCR was conducted using the LightCycler 480
RT-PCR machine and SYBR green I master mix (Roche,
Indianapolis, IN). RT-PCR oligos used are shown in Table S1.
The threshold cycle for each test gene and glyceraldehyde 3-
phosphate dehydrogenase (GADPH) was determined and an
average of threshold cycles was calculated for each test gene. Each
test gene’s average threshold cycle was normalized to the GADPH
average threshold cycle and expression relative to GADPH was
reported as 2‘‘Ct’’ GAPDH – Ct gene (where ‘‘Ct’’ indicates cycle
threshold).
Immunoblot analysis of mouse and human proteins
Mouse proteins were extracted from vaginal tissues using SDS
extraction buffer (50 mM Tris pH 7.5, 0.5% SDS, Halt Protease
inhibitor (Pierce, Rockford, IL) for 1.5 hours on ice after vortexing
with 0.5 mm glass beads (Next Advance, Averill Park, NY) five
times with 1 min vortexing and 1 min rests. Protein concentration
was measured using a Nanodrop spectrophotometer (Thermo
Scientific, Rockford, IL) and BCA assay (Pierce, Rockford, IL).
Protein lysates (50 mg) were resolved on a 10% SDS-Page gel. The
gel was transferred (wet transfer at 300 mA) to a nitrocellulose
membrane and then blocked with 5% non-fat dry milk in 16PBS.
For the detection of CD166 antigen in mouse samples, the
primary antibody was applied in blocking buffer overnight at 4uC:
Secondary antibody was used incubated at room temperature for
1 hour. Following extensive washing, the membranes were
scanned using the LI-COR Odyssey imaging system.
To detect OLFM-4 and b-actin, Vk2 cell extracts were resolved
on 4–12% Bis-Tris SDS-PAGE gels and mucin 5B was resolved on
3–8% Tris-acetate SDS-PAGE gels f. Gels were transferred to
PDVF membranes and probed with the appropriate primary and
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secondary antibodies and detected using the LI-COR Odyssey
imaging system.
Animals
All animal experiments were reviewed and approved by the
Institutional Animal Care and Use Committee (IACUC) at SRI
International and were performed in accordance with relevant
guidelines and regulations in a facility accredited by the
Association for the Assessment and Accreditation of Laboratory
Animal Care International (AAALAC).
Mouse vaginal irritation studies
Female CD1 mice were purchased from Harlan Laboratories
(Livermore, CA) and were housed in hanging polypropylene cages
with hardwood chip bedding; Purina rodent chow #5002 and
reverse osmosis purified water were provided ad libitum. All mice
(7–9 weeks of age) were hormonally synchronized with two
subcutaneous doses of 3 mg of medroxyprogesterone acetate on
days 28 and 21. The mice were randomized into treatment
groups consisting of between 6 and 12 animals per group per study
and were dosed daily for 11 days with 50 ml of the microbicide
candidates using a luer-lock syringe attached to a 20-gauge
applicator inserted 0.8 cm into the vagina. Mouse vaginal brush
collection (7 hours after dosing) was done using MicroBrush X
(MicroBrush International, Grafton, WI). Brushes were pre-wetted
in saline and inserted approximately 0.8 cm into the vaginal
cavity. The brushes were turned 90 degrees clockwise and
counterclockwise three times, removed, and placed in saline
containing 16protease inhibitor cocktail (Thermo Scientific). Any
visual presence of blood was noted but not scored. Vaginal brush
samples were collected on days 7 and 10. For the first two studies,
a single brush sample per mouse per collection day was obtained,
but on the last two studies, three brushes were used per mouse per
collection day to maximize the yield of sample recovery. Each
individual brush was placed into 0.1 ml of 16PBS pH 7.6 plus 16
protease inhibitors (Thermo Scientific). The brushes were vortexed
in the collection buffer and in the cases where multiple brushes
were used, the samples were pooled, mixed, aliquoted, and snap
frozen in dry ice/ethanol prior to storage at 280uC. Vaginas were
harvested on the final day of the study and snap frozen using dry
ice/ethanol baths prior to storage at 280uC.
Rabbit vaginal irritation studies
Female white New Zealand White rabbits (20–28 weeks of age)
were obtained from Harlan Laboratories; and were housed
individually in stainless steel cages; Teklad Rabbit Diet and
reverse osmosis purified water were provided ad libitum. Animals
were randomized into treatment groups consisting of 6 animals per
group per study and one day prior to dosing the vaginal cavities
were washed with 1 ml sterile 0.9% saline solution. The rabbits
were dosed daily for 10 days with 1 ml of the microbicide
candidates using a syringe attached to a lightly curved 6 inch
stainless steel ball-tipped cannula that was inserted approximately
5–6 inches into the vagina. On days 7 and 10 (collection 7 hours
after last dose), sterile cotton tipped swabs were used to collect
vaginal cavity material. Three cotton swabs were used per rabbit
per collection day. Each individual swab was placed into 0.5 ml of
16 PBS pH 7.6 plus 16 protease inhibitors (Thermo Scientific).
The swabs were vortexed in the collection buffer and all three
collection tubes per rabbit were pooled, mixed, aliquoted, and
snap frozen in liquid nitrogen prior to storage at 280uC.
ELISA assays
Vaginal brush samples were thawed and tested using the
individual kit’s instructions. Briefly, each dilution of the standard
was run in triplicate and samples were run in duplicate. The OD
settings for each ELISA were set by the manufacturer. Values
above or below the standard curve are reported as having a value
equal to the highest or lowest value in the standard for the kit.
Plates were scanned using a Spectramax 2 plate reader (Molecular
Devices, Sunnyvale, CA). Generation of standard curves, deter-
mination of unknown protein concentrations, and statistical
calculations were accomplished using GraphPad Prism software.
Vaginal tissue protein extraction for proteomic analysis
Vaginal tissue samples were thawed on ice, weighted, and
washed with PBS buffer. For tissue protein extraction, approxi-
mately 100 mg vaginal tissue was minced into 2 mm pieces in
1 ml lysis buffer (50 mM Tris, pH 7.4, 0.5% SDS, EDTA-free
protease inhibitor cocktail). Approximately 0.2 ml glass beads
(0.5 mm, Sigma-Aldrich, St. Louis, MO) were added to each
sample. Subsequently, samples were homogenized 5 times with
1 min for each time by a Bullet-Blender (Next Advance, Averill
Park, NY) at 4uC and then left on ice for 1 hour. Debris was
removed by centrifugation at 12,000 g for 15 min at 4uC, and
supernatants were stored at 280uC for proteomics sample
preparation. Total protein of the samples was measured using a
NanoDrop 2000 (Thermo Scientific, USA).
Proteomics sample preparation and TMT labeling
Filter-aided sample preparation (FASP) using 10k cutoff filters,
developed by Mann [30], was applied to purify and digest both
brush samples and tissue protein lysates. Briefly, 600 mL brush
sample or 200 mL tissue protein lysate was transferred into a
1.5 mL Microcon YM-10 centrifugal unit (Millipore, Billerica,
MA, USA). Protein reduction, alkylation, and tryptic digestion
were performed step by step in the centrifugal unit. After overnight
tryptic digestion at 37uC, the peptides were eluted twice with
150 mL 50 mM ammonium bicarbonate. The total protein or
peptide concentration in each step was measured using NanoDrop
2000. The eluted peptides were dried by vacuum centrifugation
and then resuspended in 50 mM Tetraethylammonium bromide
(TEAB) for Tandem Mass Tag (TMT) labeling.
50 mg digested peptides from each tissue sample and 10 mg
peptides from each brush sample were incubated with an amine-
reactive 6-plex TMT tag (Thermo Scientific, USA) for 2 hours at
room temperature. In mouse studies 1 and 2, the digested peptides
from brush samples from the same group of animals were pooled
together for TMT labeling due to low peptide content. Reactions
were quenched by adding 8 mL 5% hydroxylamine and incubated
at room temperature for 15 min. The labeled peptides were then
combined together and excess TMT tags were removed by a
368 mm SCX trap column then desalted by a 368 mm C18 RP
trap column (Bruker-Michrom, CA, USA). Purified labeled
peptides were dried by vacuum centrifugation and then resus-
pended in 0.1% formic acid (FA) for Multidimensional Protein
Identification Technology (MudPIT) analysis.
Nano-LC-MS/MS
Each TMT labeled sample was separated using a nano-LC
system (Agilent 1200, Palo Alto, CA, USA) and analyzed with an
LTQ-XL Orbitrap ETD (Thermo Fisher Scientific, San Jose, CA,
USA) equipped with a nano-ESI source. Full MS spectra were
acquired in positive mode over a 350–1800 m/z range, followed by
four CID (collision induced dissociation) and HCD (higher-energy
Biomarkers and Microbicide Toxicity
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collisional dissociation) events on the four most intense ions
selected from the full MS spectrum and using a dynamic exclusion
time of 30 s [31]. Four CID scans (maximum inject time 100 ms,
minimum signal threshold 500 counts, collision energy 35%,
activation time 30 ms, isolation width 1.0 m/z) were used for
peptide identification and four corresponding HCD scans
(maximum inject time 300 ms, minimum signal threshold 500
counts, collision energy 45%, activation time 30 ms, isolation
width 1.0 m/z) were used for quantitation.
Database Search
Acquired tandem mass spectra were searched against the
European Bioinformatics Institute International Protein Index
mouse protein database (version 3.73). A decoy database
containing the reverse sequence of all the proteins was appended
to estimate false discovery rate (FDR). The search was performed
using SEQUEST algorithm incorporated in Proteome Discoverer
1.3.0.339 (Thermo Finnigan, CA, USA). The precursor mass
accuracy was limited to 13 ppm and fragment ion mass tolerance
was set at 1.1 Da. Fully tryptic enzyme specificity and up to two
missed cleavages were allowed. Fixed modifications included
carbamidomethylation on cysteines and variable modifications
included oxidation on methionines and TMT adduction to
peptide N-termini, lysines, and tyrosines. Peptide quantitation
was also performed in Proteome Discoverer 1.3.0.339 in the same
workflow. A TMT 6-plex quantitation method was used for HCD-
based quantitation. Mass tolerance was set at 150 ppm for
reporter TMT tags. The intensity of each peptide was normalized
to protein median intensity before calculating the ratio of different
tags from the same peptides. Protein quantitation was calculated
based on the data of each quantified peptide.
Statistical analysis
For ELISAs and RT-PCR assays, Student’s T-tests were
conducted with Welch’s correction for compound groups versus
vehicle controls. P values #0.05 are considered.
For proteomics analysis, FDR calculated through a decoy
database search was set as 0.05 for both protein identification and
quantitation. For each study, standard deviation was calculated for
the protein level alteration in every group.
Figure 1. Quantitative proteomic analysis of mouse brush samples. (A) LC-MS/MS analysis of mouse proteins in vaginal brush samples that
are affected by treatment with N9 (open, black circles) or BZK (closed squares). Shown are proteins that are increased compared to vehicle controls.
The following proteins are depicted in the graph: fibrinogen alpha polypeptide isoform 2 (FGA), plasminogen (PLG), apolipoprotein A-1 (Apo A-1),
and apolipoprotein C-1 (Apo C-1). Each data point represents the average of three replicates per individual experimental study. Only proteins shown
to change in four studies are represented. (B) ELISA analysis of mouse proteins in vaginal brush samples that are increased in response to treatment
with 8% N9 or 2% BZK. Statistical analysis was performed using a two-tailed Student’s T-test of N9 and BZK samples compared to vehicle controls
(**** = p#0.0001, ** = p#0.01). (C) ELISA analysis of mouse proteins in vaginal brush samples that are increased in response to treatment with vehicle,
1% N9, 4% N9, or 8% N9. Statistical analysis was performed using a two-tailed student’s t-test of N9 and BZK samples compared to vehicle controls
(**** = p#0.0001, *** = p#0.001, ** = p#0.01, * = p#0.05, NS = not significant).
doi:10.1371/journal.pone.0110980.g001
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Results
Proteomic analysis of mouse vaginal brush and tissue
samples reveal changes in several proteins after
treatment with N9 and BZK
To identify protein changes induced by vaginal microbicide
candidates with an undesirable safety profile, mice were treated
with either vehicle, 8% N9, 2% BZK, or 1% tenofovir (a non-toxic
microbicide) [32] for 10 consecutive days (as per standard
preclinical evaluations in mice and rabbits [23]), with mucosal
samples and tissue samples collected at day 7 and 10 for analysis
by 2D LC-MS/MS, respectively.
Proteins from vaginal brushes. Changes in proteins
present in mucosal secretions upon treatment with toxic
compounds can be exploited to define biomarkers of toxicity. In
this study, mucosal secretions were collected by brush sampling.
Proteins that showed a consistent .2-fold change relative to
vehicle control in at least two studies were selected for further
analysis. A total of 1017 proteins were identified with a false
discovery rate (FDR) cutoff of 0.05. After 7 days exposure to toxic
microbicides, a total of 10 proteins were selected for further
analysis (Table 1). Six proteins were increased upon exposure to
N9 and BZK, while 4 proteins decreased. Notably the increased
proteins are thought to be serum derived, probably as a result of
exudates due to the erosive nature of the microbicides. These
consisted of apolipoprotein A-1 (Apo A-1; range change 2 to 7-fold
for N9 and 5 to 13-fold for BZK), apolipoprotein C-1 (Apo C-1;
range change 3 to 12-fold and 3 to 12-fold for BZK), fibrinogen
alpha polypeptide isoform 2 (FGA; range change 3 to 9-fold and 2
to 8-fold for BZK), plasminogen (PLG; range change 2 to 19-fold
and 2 to 8-fold for BZK), heat shock cognate 71 kDa protein
(HSPA8; range change 3 to 4-fold for both N9 and BZK), and
Corticosteroid-binding globulin (SERPINA6; range change 2 to
21-fold and 3 to 31-fold for BZK), respectively (Figure 1A and
Table 1). In contrast the following four proteins were decreased
in vaginal brush samples (Table 1 and Figure 2): peptidoglycan
recognition protein 1 (PGLYRP-1; range change 6 to 50-fold for
N9 and 5 to 52–fold for BZK), mucin 5 subtype B (mucin 5B,
range change 16 to 20-fold for N9 and 20 to 50-fold for BZK),
destrin (DSTN, range change 2.5 to 7-fold for N9 and 3 to 10-fold
for BZK), and carbonyl reductase 3 (CAR3, range change 2.5 to 7-
fold for N9 and 2 to 10-fold for BZK). These proteins are
produced by vaginal tissue and are thought to confer protection
against microorganisms.
Tenofovir treatment had no significant effect on the expression
levels of those proteins, with the exception of Apo C-1 and
PGLYRP-1, which were decreased 4-fold and increased 3-fold in
vaginal brush samples, respectively. A summary of their known or
putative biological functions of the proteins affected by N9 and
BZK treatment is listed in Table S2.
Proteins that were consistently upregulated in four replicate
proteomic experiments (Figure 1A) were then confirmed by
ELISA analysis. Upon exposure to N9, Apo A-1 was increased an
average of 12-fold over vehicle (ranging from a 4 to 29-fold
increase) or tenofovir control and plasminogen was elevated an
average of 27-fold (ranging from an 18 to 71-fold increase). Both
Apo C-1 and fibrinogen alpha polypeptide isoform 2 (FGA)
showed a lesser increase, averaging ,3-fold each (ranging from a
0.53 decrease to a 7.4-fold increase and a 1.55 to 6 fold-increase,
respectively) (Figure 1B). Levels of these proteins were even
higher following treatment with BZK when compared with
vehicle/tenofovir control treatment. Apo A-1 showed a 17-fold
increase (range 9–36-fold); plasminogen increased 76-fold (range
15 to 191-fold), Apo C-1 increased 5-fold (range 1 to 13-fold), and
FGA showed a 7-fold increases, (range 4 to 12-fold), respectively.
The biological function of these proteins is summarized in Table
S2. The identified proteins are all serum proteins possibly present
in the brush sample due to the tissue damaging effect of N9 and
BZK, which in few circumstances caused bleeding in the vaginal
cavity (not shown). Blood was predominantly found in brush
samples in mice and rabbits treated with BZK, but was only rarely
observed in animals (mice or rabbits) treated with N9, emphasizing
that the presence of blood could not be used as a predictor to
detect toxic effects of test articles. To cover a range of
concentrations of N9 that were representative of the dose used
in clinical trials (3.5%) and to reduce the disruption of the cervical
epithelium, we examined the levels of Apo A-1, Apo C-1, FGA,
and plasminogen using lower concentrations of N9 (1%, 4%, and
8%). With the exception of Apo C-1, N9 exhibited a dose
dependent increase of each marker in vaginal brush samples. Apo
A-1 and FGA showed a marked increase with as little 1% N9 and
all 4 proteins were elevated with 4% N9 which increased further
with 8% N9 (Figure 1C). These data suggest that these proteins
could be incorporated into a rapid and sensitive set of biomarkers
for the evaluation of microbicide toxicity. In addition, one
experiment was conducted with a clinical trial formulation of
Buffergel, a microbicide that was safe but failed to protect women
against HIV. Buffergel treatment, like tenofovir did not demon-
strate an increase in these proteins when tested by ELISA (Figure
S1).
Proteins from Vaginal Tissues. The use of proteomics for
identification of proteins in vaginal fluids revealed several proteins
altered by treatment with N9 and BZK; however, focusing only on
vaginal secretions limits the potential pool of markers that could be
utilized for evaluating microbicide toxicity. Therefore, we
proceeded to analyze the changes induced by N9 and BZK in
vaginal tissues. Proteomic analysis of vaginal tissue lysates revealed
an average of 1,585 unique proteins. Of these, five proteins were
found to be consistently down-regulated (average of 2- to 3-fold)
(Table 1 and Figure 3A), including PGLYRP-1 (range 2 to 3-
fold for both N9 and BZK), CD166 (range 2 to 2.5-fold for N9 and
2.5 to 3-fold for BZK), mucin 5B (range 2 to 2.5-fold for N9 and 2
to 6-fold for BZK), olfactomedin-4 (OLFM-4) (range 1 to 4-fold for
N9 and 1 to 5-fold for BZK), and anterior gradient protein 2
Figure 2. LC MS/MS proteomic analysis of mouse proteins in
vaginal brush samples that are down-regulated in response to
treatment with N9 (open, black circles) or BZK (closed squares).
Shown are proteins that were decreased relative to vehicle controls. The
following proteins are shown: peptidoglycan recognition protein 1
(PGLYRP-1), mucin 5 subtype B (mucin 5B), destrin, and carbonyl
reductase 3 (CAR3). Each data point represents the average of three
replicates per individual experimental study. Only proteins shown to
change in a minimum of two studies are represented.
doi:10.1371/journal.pone.0110980.g002
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homolog (AGR2) (range 2 to 4-fold for N9 and 1 to 15-fold for
BZK.
The down-regulation was confirmed by RT-PCR analysis
(Figure 3B) and CD166 was further confirmed by immunoblot
(Figure 3C). Changes in mRNA expression levels could be
detected for these proteins following treatment with as little as 1%
N9 gel (Figure S1B). Tenofovir treatment had minimal effect (less
than two-fold) on these protein levels in vaginal tissues, suggesting
that the changes observed were restricted to compounds with toxic
activities. Among all proteins identified from vaginal brushes and
tissues, PGLYRP-1 and mucin 5B were the only two proteins
affected by treatment in both set of samples. In summary, these
results highlight the limited number of proteins in the vaginal
tissues that change upon exposure to N9 and BZK, potentially
identifying new candidate biomarkers to evaluate safety of
candidate microbicides.
Treatment with N9 and BZK up-regulates the expression
of several chemokine genes
One of the limitations of our proteomic approach is the
difficulty in reliably detecting proteins of low molecular weight
(e.g. chemokines). Previously we demonstrated that the chemokine
CCL2 (MCP-1) was up-regulated in rabbit brush and tissue
samples when treated with N9 and BZK [18], and other groups
have shown CCL2 and CCL5 (RANTES) to be up-regulated in
the MVI model in response to treatment with N9 [33]. To
determine if the vaginal levels of additional chemokines were
affected by treatment with N9 or BZK, we selected chemokines
Figure 3. Quantitative proteomic and RT-PCR analysis of mouse tissue samples. (A) LC MS/MS proteomic analysis of mouse vaginal tissue
samples down-regulated in response to treatment with N9 (open, black circles) or BZK (black squares). The following proteins are depicted in the
graphs: peptidoglycan recognition protein 1 (PGLYRP-1), CD166 antigen (CD166), mucin 5 subtype B (mucin 5B), olfactomedin-4 (OLFM-4), and
anterior gradient protein 2 homolog (AGR2). Each data point represents the average of three replicates per individual experimental study. Only
proteins shown to change in a minimum of two studies are represented. (B) RT-PCR analysis of mouse mRNA expression. Relative expression levels
are normalized to Glyceraldehyde 3-phosphate dehydrogenase (GADPH). Statistical analysis was performed using a two-tailed Student’s T-test of N9,
BZK, and tenofovir samples compared to vehicle controls (*** = p#0.001, * = p#0.05, NS = not significant). (C) Immunoblot of mouse CD166 antigen.
Three mice per condition were analyzed. The CD166 signal was normalized to the b-actin signal for quantitation. Statistical analysis was performed
using a two-tailed student’s T-test of N9 and BZK samples compared to vehicle controls (*** = p#0.001, ** = p#0.01).
doi:10.1371/journal.pone.0110980.g003
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that had been shown to be upregulated during a preliminary
microarray analysis (not shown) and performed RT-PCR for
CCL3, CCL5 and CCL7 on rabbit vaginal tissue samples. Our
analysis showed upregulated expression of CCL3 and CCL7 in
response to N9 or BZK, but not in response to treatment with
tenofovir or vehicle (Figure 4). While CCL5 was increased upon
exposure to N9, as previously reported [33], its expression was not
affected by BZK, indicating that CCL5 is not consistently
upregulated by all compounds with toxic potential.
Treatment with N9 and BZK induces similar changes in
rabbit brush samples
Although the RVI model is considered the preferred model for
preclinical evaluation of vaginal microbicides, its many limitations
have prompted investigators to develop other animal models. The
MVI model has been used extensively to examine the efficacy of
potential topical microbicides in the prevention of HSV-2
infection [34] and several studies have provided evidence for the
MVI model to be a valuable tool for preclinical assessment of
toxicity associated with exposure to candidate microbicides
[33,35]. To provide further evidence in support of using the
MVI model, we performed a proteomic analysis to determine
whether proteins affected by N9 and BZK treatment in mice were
consistent across species. For this evaluation, rabbits were treated
with the same concentrations of N9 and BZK used in the mouse
studies, and brush samples were analyzed. Our proteomic analysis
from N9 or BZK treated samples showed a concordance between
mouse and rabbit with upregulation of FGA, Apo A-1, Apo C-1,
plasminogen, and corticosteroid binding protein (Table 2).
ELISA assays confirmed the changes observed by proteomics
analysis for FGA, Apo A-1, and plasminogen in brush samples
(Figure 5), with no significant effect observed upon treatment
with tenofovir. Apo C-1 showed a similar trend although the
changes were not statistically significant (not shown). The lack of
reagents specific for rabbit proteins impeded the testing of
additional markers. In addition, the proteomics analysis also
confirmed the down-regulatory effect of N9 and BZK on destrin
and proteins from the mucin family; in rabbit we detected down-
regulation of mucin 1 rather than mucin 5B. Some of the other
proteins affected by N9 and BZK in MVI model (such as CAR3,
and heat shock cognate 71 kDa protein) were not identified in our
proteomic analysis in the rabbit study, and we see two possible
explanations. In the first case, the anatomy of rabbits may play a
critical role as the bladder empties into the vagina, therefore
diluting all proteins or test articles present in the vagina. As a
consequence, the residence time of the test articles can be
significantly impacted, therefore masking its real impact on tissues.
Alternatively, some of the proteins identified in mice did not
appear represented in the rabbit proteomic database and therefore
would not be detected using our proteomic approaches.
N9 treatment of a human vaginal epithelial cell line
up-regulates the mRNA expression levels of
proinflammatory proteins while reducing the expression
levels of mucin 5B, and OLFM-4
Due to the difficulty in obtaining human vaginal tissue from
patients treated with N9 or BZK, we tested the effects of N9 on
cultured human vaginal epithelial cells. For these studies we
selected human Vk2 (E6/E7) cells, a vaginal epithelial cell line,
frequently used for vaginal studies [36–38]. Expression of OLFM-
4, mucin 5B and PGLYRP-1 in untreated cells was evaluated
using RT-PCR and immunoblots. VK2 cells had detectable levels
of mRNA and protein for OLFM-4 and mucin 5B mRNA
(Figure S2) but not PGLYRP-1 (data not shown). To determine
whether N9 may down-regulate the expression of these genes in
Vk2 cells, cultures were treated with N9 and transcript changes
were monitored following treatment. As was previously demon-
strated [38], N9 is highly toxic to Vk2 cells. We used 0.001% N9
as 80% of the cells remained viable after 24 hours at this
concentration (Figure S3). Expression of OLFM-4 was highly
reduced by 24 hours (14.6-fold, ranging from 12.5 to 25-fold),
while mucin 5B, although already significantly reduced at
24 hours (2.5 fold, ranging from 2 to 3-fold) showed a total
decrease of 12.4-fold (ranging from 9 to 14-fold) at 48 hours
(Figure 6, right panel). As previously reported [38], N9
increased the expression of the pro-inflammatory marker cox2
10-fold (ranging from 8 to 15-fold) within 6 hours of treatment
(Figure 6, left panel) compared to vehicle control cells. We also
found that IL-8 was increased approximately 3-fold (ranging from
2 to 4-fold). The data obtained from cell lines suggests that selected
proteins identified in proteomic assays in mice and rabbits may in
fact serve as predictive biomarker for human studies.
Discussion
Monitoring changes in the vagina that can efficiently and
reliably predict the safety of candidate microbicides is an
important step during preclinical and clinical studies of putative
new microbicides. For preclinical evaluations, use of the RVI
model has long been the primary model to assess the toxicity of
vaginal products. This model focuses on histopathological
observations and has been repeatedly shown to be less than
optimal for preclinical assessments as it is not a good structural
model for the human vagina due to the differences in the
epithelium (squamous in human versus columnar in rabbits) and
position of the urethra inside the vagina. In addition, the study
required euthanizing ,30–35 rabbits for each microbicide
evaluated. The unfortunate findings during human clinical trials
with N9, and cellulose sulfate (CS), both of which enhanced HIV
acquisition [12,13], have clearly pointed out the need for more
comprehensive and meaningful testing.
Although considerable effort has been directed toward the
discovery of biomarkers that can be linked to microbicide-induced
cervicovaginal inflammation [5,26,39,40], currently there is no
FDA approved panel of biomarkers that can be used to
demonstrate that changes in specific proteins will increase
susceptibility to HIV infection. Identifying proinflammatory
markers is a rational approach, and we and others [4,18,33] have
reported the presence of inflammatory mediators and chemokines
Figure 4. RT-PCR analysis of mouse CCL3, CCL5, and CCL7 gene
expression. Relative expression levels are normalized to Glyceralde-
hyde 3-phosphate dehydrogenase (GADPH). Statistical analysis was
performed using a two-tailed Student’s T-test of N9, BZK, and Tenofovir
samples (3 replicates) compared to vehicle controls (*** = p#0.001,
** = p#0.01,* = p#0.05, NS = not significant).
doi:10.1371/journal.pone.0110980.g004
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that could be responsible for the recruitment of monocytes and T
cells in the vaginal milieu. Although the presence of chemokine
attractants such as CCL2, CCL3, CCL5, MIP-2, and IL-1b,
provides a potential rationale for the increased HIV infection rate
observed during clinical trials [13], our data suggests that focusing
only on proinflammatory proteins provides an incomplete picture.
Considering the complexity of the microenvironment of vagina
and the presence of different cytokines under various physiological
conditions [40], an attempt to predict microbicide toxicity using
cytokines and chemokines alone may not be sufficient. Inclusion of
additional biomarkers that can detect changes in the epithelium
barrier and local mucosal immunity may provide a more accurate
indicator of potential safety issues with a product.
In this study we have used an untargeted LC-MS/MS based
quantitative proteomic approach to identify and compare the
qualitative and quantitative changes induced by N9 and BZK in
both mice and rabbits. Our studies identified a panel of proteins
that are altered during treatment with N9 and BZK in the mucosal
vaginal environment. Using the MVI model, we identified six
proteins (Apo A-1, Apo C-1, FGA, plasminogen, destrin, CAR3),
whose levels were increased only in the vaginal brush samples
(Figure 1 and 2). The elevated levels of these proteins are
consistent with traces of blood in collected brush samples from
some animals (mice and rabbits) treated with N9 and BZK. In
addition, three proteins (CD166, OLFM-4, AGR2) were de-
creased only in the vaginal tissues and two proteins (mucin 5B and
PGLYRP-1) were down-regulated in both brush and vaginal tissue






































































































































































































































































































































































































































































































































































































Figure 6. mRNA expression of cyclooxygenase-2 (cox2),
Interleukin 8 (IL-8), mucin 5B, and olfactomedin-4 (OLFM-4)
in Vk2 cells treated with N9 for 6, 24, or 48 hours. Shown is the
average of two replicate experiments, each sample performed in
duplicate for each time point. Also shown is the relative expression
levels of N9 treated cells compared to untreated cells, which was set to
an expression level of 1 (dashed line). Statistical analysis was performed
using a two-tailed Student’s T-test of N9 samples compared to
untreated controls at each time point (*** = p#0.001, ** = p#0.01,
* = p#0.05, NS = not significant).
doi:10.1371/journal.pone.0110980.g006
Figure 5. ELISA analysis of rabbit proteins in vaginal brush
samples increased in response to treatment with N9 or BZK.
Statistical analysis were performed using a two-tailed Student’s T-test of
N9 and BZK samples compared to vehicle controls (** = p#0.01, * = p#
0.05, NS = not significant).
doi:10.1371/journal.pone.0110980.g005
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probably shed into the mucosa. Using ELISA assays we also
identified two additional chemokines, CCL3 and CCL7, and
confirmed the presence of two previously known chemokines,
CCL5 [33] and our previously reported CCL2 [18], as additional
proteins that could be added to a potential biomarker panel. By
proteomics analysis we didn’t consistently detect changes in
cytokines or chemokines known to be altered following treatment
with N9, fact that could be due to the loss of small size of the
proteins during sample preparation procedure. Therefore, we
performed RT-PCR to evaluate changes on those small proteins.
Among the down-regulated proteins, OLFM-4, PGLYRP-1 and
mucin 5B, have been reported to play important roles in
protection against microbial infection [41–46]. OLFM-4 is known
to be a suppressor of proinflammatory responses in gut epithelium
[45], and it has been implicated in maintenance of persistent
Helicobacter pylori infection where the bacteria use OLFM-4 to
suppress the inflammatory response by the intestinal epithelium
[45]. Loss of OLFM-4 results in rapid clearance of H. pylori due to
an aggressive host inflammatory response that includes the release
of CCL3, CCL5, and CCL7 [45], chemokines that were identified
in this screen. The localized production of these chemokines may
be responsible for the recruitment of HIV susceptible monocytes
and T cells to sites of vaginal damage induced by the toxic
microbicide compounds [18,33]. Additionally, epithelial cells have
been shown to produce chemokines as well as express chemokine
receptors [47,48], which play a role in the migration of immune
modulating cells. OLFM-4 may play a similar role in the vagina by
suppressing an inflammatory response to vaginal microflora and
maintaining proper microbe and tissue homeostasis in the vaginal
cavity.
PGLYRP-1 is known to be highly bactericidal [49,50] and like
OLFM-4, also appears to play a role in suppressing inflammation
[51]. Thus, PGLYRP-1 could play a dual role in maintaining
normal microflora and targeted killing of pathogenic bacteria.
Mucin 5B has been shown to be required for respiratory tract
health, and muc5b2/2 mice exhibit severe morbidity and mortality
due to an inability to clear routine debris (e.g., hair), leading to
persistent bacterial infection of the lungs [44]. Additionally,
human mucin 5B has demonstrated anti-HIV properties in vitro,
presumably because of interactions between mucin 5B and the
glycoproteins found in the viral envelope [52]. AGR2, one of the
proteins that we found to be down-regulated in vaginal tissues, has
been implicated in the production of mucus [53,54], so the
reduction in AGR2 may have affected levels of mucin 5B protein.
Thus mucin 5B may also play two roles in the vagina by
maintaining the proper bacterial flora as observed in airway
epithelium and providing defense against viral pathogens like
HIV.
Given the diversity of the vaginal microflora, there must be a
delicate balance between allowing for persistent growth of normal
bacterial flora and suppression of an inflammatory response to
remove them. N9 is known to alter the normal microflora of the
vagina, including a marked decrease in several lactobacillus species
with a subsequent increase in other potentially harmful bacterial
species [55] that could induce an inflammatory response. We
propose a model (Figure 7) in which these anti-inflammatory/
protective proteins provide a stout epithelial barrier that support a
balanced microbiota in the vagina; treatment with compounds
such as N9, by inducing inflammation, causes damage to the
vaginal epithelium, reduces the levels of these proteins leading to
recruitment and dangerous exposure of HIV susceptible cells at
the sites of tissue damage.
Supporting Information
Figure S1 Quantitative proteomic and RT-PCR analysis
of mouse brush and tissue samples from mice treated
with vehicle, buffergel, Tenofovir, and/or a range of N9
concentrations. (A) ELISA analysis of day 7 mouse vaginal
brush samples isolated from animals treated with either vehicle,
Buffergel, or 1% Tenofovir. (B) mRNA expression analysis of
CD166 antigen (CD166), peptidoglycan recognition protein 1
(PGLYRP-1), olfactomedin-4 (OLFM-4), mucin 5 subtype B
(mucin 5B), and anterior gradient protein 2 homolog (AGR2)
isolated from day 10 mouse vaginal tissues treated with vehicle,
1%, 4%, or 8% N9, Buffergel, or 1% Tenofovir. Statistical analysis
was performed using a two-tailed Student’s T-test of N9 samples
compared to untreated controls at each time point (*** = p#0.001,
** = p#0.01, * = p#0.05, NS = not significant).
(EPS)
Figure S2 Analysis of mucin 5B expression in Vk2 cells.
mRNA (left) and protein expression (right) of mucin 5B
and olfactomedin-4 (OLFM-4) in untreated Vk2 cells.
Shown are two replicate cDNA samples amplified using gene-
specific RT-PCR oligonucleotides, and duplicate protein samples
resolved by SDS-PAGE, then blotted to PDVF membranes and
stained with anti-mucin 5B, anti-OLFM-4, or anti-actin antibod-
ies. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is
included as a loading control for the RT-PCR.
(EPS)
Figure S3 Viability of Vk2 cells treated with 0.001% N9
for 6, 24, and 48 hrs. Viability testing was performed using
CellTiter Glo which measures ATP levels in the cells.
(EPS)
Figure 7. Model for the protective roles of mucin 5B,
olfactomedin-4 (OLFM-4), and peptidoglycan recognition pro-
tein 1 (PGLYRP-1) in vaginal epithelium. In normal epithelium
(top) these proteins maintain a balanced microflora and suppress
inflammation. However, when exposed to toxic microbicides such as N9
(bottom) the epithelium becomes inflamed causing bleeding and
release of serum proteins into the vaginal cavity. In addition, the
microflora is altered leading to dysbiosis which could boost the
inflammation response. The result is an influx and expansion of
leukocytes that may be susceptible to HIV.
doi:10.1371/journal.pone.0110980.g007
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Table S1 List of RT-PCR primers.
(DOCX)




We would like to thank Dr. Paul Stein for his efforts in reviewing the
manuscript and Dr. Hao Zhang for his guidance. We would also like to
thank SRI International’s Laboratory Animal Management Department
for help with animal husbandry and help with carrying out the animal
studies.
Author Contributions
Conceived and designed the experiments: SF BS AD. Performed the
experiments: SF BS BR JF MGW KS YY. Analyzed the data: SF BS BR
AD. Wrote the paper: SF BS JM AD.
References
1. Catalone B, Kish-Catalone T, Neely E, Budgeon L, Ferguson M, et al. (2005)
Comparative safety evaluation of the candidate vaginal microbicide C31G.
Antimicrob Agents Chemother 49: 1509–1520.
2. Catalone BJ, Miller SR, Ferguson ML, Malamud D, Kish-Catalone T, et al.
(2005) Toxicity, inflammation, and anti-human immunodeficiency virus type 1
activity following exposure to chemical moieties of C31G. Biomed Pharmac-
other 59: 430–437.
3. Cohen J (2008) AIDS research. Microbicide fails to protect against HIV. Science
319: 1026–1027.
4. Cone R, Hoen T, Wong X, Abusuwwa R, Anderson D, et al. (2006) Vaginal
microbicides: detecting toxicities in vivo that paradoxically increase pathogen
transmission. BMC Infectious Diseases 6: 90.
5. Fichorova R, Tucker L, Anderson D (2001) The molecular basis of nonoxynol-9-
induced vaginal inflammation and its possible relevance to human immunode-
ficiency virus type 1 transmission. J Infect Dis 184: 418–428.
6. Honey K (2007) Microbicide trial screeches to a halt. J Clin Invest 117: 1116.
7. Kreiss J, Ngugi E, Holmes K, Ndinya-Achola J, Waiyaki P, et al. (1992) Efficacy
of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition
of HIV in Nairobi prostitutes. JAMA 268: 477–482.
8. Mayer KH, Peipert J, Fleming T, Fullem A, Moench T, et al. (2001) Safety and
tolerability of BufferGel, a novel vaginal microbicide, in women in the United
States. Clin Infect Dis 32: 476–482.
9. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Weir SS, et al. (1998) A controlled
trial of nonoxynol 9 film to reduce male-to-female transmission of sexually
transmitted diseases. N Engl J Med 339: 504–510.
10. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, et al. (2008)
Efficacy of Carraguard for prevention of HIV infection in women in South
Africa: a randomised, double-blind, placebo-controlled trial. The Lancet 372:
1977–1987.
11. Van Damme L, Chandeying V, Ramjee G, Rees H, Sirivongrangson P, et al.
(2000) Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal
gel, among female sex workers. COL-1492 Phase II Study Group. AIDS 14: 85–
88.
12. Van Damme L, Govinden R, Mirembe FM, Guédou F, Solomon S, et al. (2008)
Lack of Effectiveness of Cellulose Sulfate Gel for the Prevention of Vaginal HIV
Transmission. New England Journal of Medicine 359: 463–472.
13. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, et al. (2002)
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in
female sex workers: a randomised controlled trial. Lancet 360: 971–977.
14. Kish-Catalone TM, Lu W, Gallo RC, DeVico AL (2006) Preclinical evaluation
of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5.
Antimicrob Agents Chemother 50: 1497–1509.
15. Zeitlin L, Hoen TE, Achilles SL, Hegarty TA, Jerse AE, et al. (2001) Tests of
Buffergel for contraception and prevention of sexually transmitted diseases in
animal models. Sex Transm Dis 28: 417–423.
16. Kaminsky M, Szivos MM, Brown KR, Willigan DA (1985) Comparison of the
sensitivity of the vaginal mucous membranes of the albino rabbit and laboratory
rat to nonoxynol-9. Food Chem Toxicol 23: 705–708.
17. Tien D, Schnaare RL, Kang F, Cohl G, McCormick TJ, et al. (2005) In vitro
and in vivo characterization of a potential universal placebo designed for use in
vaginal microbicide clinical trials. AIDS Res Hum Retroviruses 21: 845–853.
18. Alt C, Harrison T, Dousman L, Fujita N, Shew K, et al. (2009) Increased CCL2
expression and macrophage/monocyte migration during microbicide-induced
vaginal irritation. Curr HIV Res 7: 639–649.
19. Fichorova RN, Bajpai M, Chandra N, Hsiu JG, Spangler M, et al. (2004)
Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal
microbicidal contraceptives. Biol Reprod 71: 761–769.
20. Anderson RA, Feathergill KA, Diao XH, Cooper MD, Kirkpatrick R, et al.
(2002) Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a
contraceptive antimicrobial agent. J Androl 23: 426–438.
21. Kurita T (2010) Developmental origin of vaginal epithelium. Differentiation 80:
99–105.
22. Barberini F, Correr S, De Santis F, Motta PM (1991) The epithelium of the
rabbit vagina: a microtopographical study by light, transmission and scanning
electron microscopy. Arch Histol Cytol 54: 365–378.
23. Costin GE, Raabe HA, Priston R, Evans E, Curren RD (2011) Vaginal irritation
models: the current status of available alternative and in vitro tests. Altern Lab
Anim 39: 317–337.
24. Achilles SL, Shete PB, Whaley KJ, Moench TR, Cone RA (2002) Microbicide
efficacy and toxicity tests in a mouse model for vaginal transmission of
Chlamydia trachomatis. Sex Transm Dis 29: 655–664.
25. Cone RA, Hoen T, Wong X, Abusuwwa R, Anderson DJ, et al. (2006) Vaginal
microbicides: detecting toxicities in vivo that paradoxically increase pathogen
transmission. BMC Infect Dis 6: 90.
26. Catalone BJ, Kish-Catalone TM, Budgeon LR, Neely EB, Ferguson M, et al.
(2004) Mouse model of cervicovaginal toxicity and inflammation for preclinical
evaluation of topical vaginal microbicides. Antimicrob Agents Chemother 48:
1837–1847.
27. Milligan G, Dudley K, Bourne N, Reece A, Stanberry L (2002) Entry of
inflammatory cells into the mouse vagina following application of candidate
microbicides: comparison of detergent-based and sulfated polymer-based agents.
Sex Transm Dis 29: 597–605.
28. Achilles S, Shete P, Whaley K, Moench T, Cone R (2002) Microbicide efficacy
and toxicity tests in a mouse model for vaginal transmission of Chlamydia
trachomatis. Sex Transm Dis 29: 655–664.
29. Patton DL, Kidder GG, Sweeney YC, Rabe LK, Hillier SL (1999) Effects of
multiple applications of benzalkonium chloride and nonoxynol 9 on the vaginal
epithelium in the pigtailed macaque (Macaca nemestrina). Am J Obstet Gynecol
180: 1080–1087.
30. Wisniewski JR, Zougman A, Nagaraj N, Mann M (2009) Universal sample
preparation method for proteome analysis. Nat Methods 6: 359–362.
31. Liu Y, Parman T, Schneider B, Song B, Galande AK, et al. Serum biomarkers
reveal long-term cardiac injury in isoproterenol-treated African green monkeys.
J Proteome Res 12: 1830–1837.
32. Redd AD, Mullis CE, Wendel SK, Sheward D, Martens C, et al. (2014) Limited
HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide
Trial. J Clin Microbiol 52: 844–848.
33. Galen BT, Martin AP, Hazrati E, Garin A, Guzman E, et al. (2007) A
comprehensive murine model to evaluate topical vaginal microbicides: mucosal
inflammation and susceptibility to genital herpes as surrogate markers of safety.
J Infect Dis 195: 1332–1339.
34. Roy S, Gourde P, Piret J, Desormeaux A, Lamontagne J, et al. (2001)
Thermoreversible gel formulations containing sodium lauryl sulfate or n-
Lauroylsarcosine as potential topical microbicides against sexually transmitted
diseases. Antimicrob Agents Chemother 45: 1671–1681.
35. Catalone B, Kish-Catalone T, Budgeon L, Neely E, Ferguson M, et al. (2004)
Mouse model of cervicovaginal toxicity and inflammation for preclinical
evaluation of topical vaginal microbicides. Antimicrob Agents Chemother 48:
1837–1847.
36. Fichorova RN, Yamamoto HS, Delaney ML, Onderdonk AB, Doncel GF (2011)
Novel vaginal microflora colonization model providing new insight into
microbicide mechanism of action. MBio 2: e00168-00111.
37. Wagner RD, Johnson SJ (2012) Probiotic lactobacillus and estrogen effects on
vaginal epithelial gene expression responses to Candida albicans. J Biomed Sci
19: 58.
38. Zalenskaya IA, Cerocchi OG, Joseph T, Donaghay MA, Schriver SD, et al.
(2011) Increased COX-2 Expression in Human Vaginal Epithelial Cells Exposed
to Nonoxynol-9, a Vaginal Contraceptive Microbicide that Failed to Protect
Women from HIV-1 Infection. American Journal of Reproductive Immunology
65: 569–577.
39. Fichorova R, Bajpai M, Chandra N, Hsiu J, Spangler M, et al. (2004) Interleukin
(IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal
contraceptives. Biol Reprod 71: 761–769.
40. Fichorova RN (2004) Guiding the vaginal microbicide trials with biomarkers of
inflammation. J Acquir Immune Defic Syndr 37 Suppl 3: S184–193.
41. Osanai A, Sashinami H, Asano K, Li S-J, Hu D-L, et al. (2011) Mouse
Peptidoglycan Recognition Protein PGLYRP-1 Plays a Role in the Host Innate
Immune Response against Listeria monocytogenes Infection. Infection and
Immunity 79: 858–866.
42. Liu C, Gelius E, Liu G, Steiner H, Dziarski R (2000) Mammalian Peptidoglycan
Recognition Protein Binds Peptidoglycan with High Affinity, Is Expressed in
Neutrophils, and Inhibits Bacterial Growth. Journal of Biological Chemistry 275:
24490–24499.
43. Liu C, Xu Z, Gupta D, Dziarski R (2001) Peptidoglycan Recognition Proteins: A
Novel Family of Four Human Innate Immunity Pattern Recognition Molecules.
Journal of Biological Chemistry 276: 34686–34694.
Biomarkers and Microbicide Toxicity
PLOS ONE | www.plosone.org 11 October 2014 | Volume 9 | Issue 10 | e110980
44. Roy MG, Livraghi-Butrico A, Fletcher AA, McElwee MM, Evans SE, et al.
(2014) Muc5b is required for airway defence. Nature 505: 412–416.
45. Liu W, Yan M, Liu Y, Wang R, Li C, et al. (2010) Olfactomedin 4 down-
regulates innate immunity against Helicobacter pylori infection.
46. Liu W, Yan M, Sugui JA, Li H, Xu C, et al. (2013) Olfm4 deletion enhances
defense against Staphylococcus aureus in chronic granulomatous disease. The
Journal of Clinical Investigation 123: 3751–3755.
47. Mulayim N, Palter SF, Kayisli UA, Senturk L, Arici A (2003) Chemokine
receptor expression in human endometrium. Biol Reprod 68: 1491–1495.
48. Patterson BK, Landay A, Andersson J, Brown C, Behbahani H, et al. (1998)
Repertoire of chemokine receptor expression in the female genital tract:
implications for human immunodeficiency virus transmission. Am J Pathol 153:
481–490.
49. Kashyap DR, Wang M, Liu LH, Boons GJ, Gupta D, et al. (2011) Peptidoglycan
recognition proteins kill bacteria by activating protein-sensing two-component
systems. Nat Med 17: 676–683.
50. Lu X, Wang M, Qi J, Wang H, Li X, et al. (2006) Peptidoglycan recognition
proteins are a new class of human bactericidal proteins. J Biol Chem 281: 5895–
5907.
51. Saha S, Qi J, Wang S, Wang M, Li X, et al. (2009) PGLYRP-2 and Nod2 are
both required for peptidoglycan-induced arthritis and local inflammation. Cell
Host Microbe 5: 137–150.
52. Habte H, de Beer C, Lotz Z, Roux P, Mall A (2010) Anti-HIV-1 activity of
salivary MUC5B and MUC7 mucins from HIV patients with different CD4
counts. Virology Journal 7: 269.
53. Park S-W, Zhen G, Verhaeghe C, Nakagami Y, Nguyenvu LT, et al. (2009) The
protein disulfide isomerase AGR2 is essential for production of intestinal mucus.
Proceedings of the National Academy of Sciences 106: 6950–6955.
54. Zhou Y, Shapiro M, Dong Q, Louahed J, Weiss C, et al. (2002) A calcium-
activated chloride channel blocker inhibits goblet cell metaplasia and mucus
overproduction. Novartis Found Symp 248: 150–165; discussion 165–170, 277-
182.
55. Ravel J, Gajer P, Fu L, Mauck CK, Koenig SS, et al. (2012) Twice-daily
application of HIV microbicides alter the vaginal microbiota. MBio 3.
Biomarkers and Microbicide Toxicity
PLOS ONE | www.plosone.org 12 October 2014 | Volume 9 | Issue 10 | e110980
